Cargando…
Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use
Monoclonal antibodies (mAbs) are attractive therapeutics for treating a wide range of human disorders, and bind to the antigen through their complementarity-determining regions (CDRs). Small stable proteins containing structurally retained CDRs are promising alternatives to mAbs. In this report, we...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972867/ https://www.ncbi.nlm.nih.gov/pubmed/31964960 http://dx.doi.org/10.1038/s41598-020-57713-4 |
_version_ | 1783489925215158272 |
---|---|
author | Kadonosono, Tetsuya Yimchuen, Wanaporn Ota, Yumi See, Kyra Furuta, Tadaomi Shiozawa, Tadashi Kitazawa, Maika Goto, Yu Patil, Akash Kuchimaru, Takahiro Kizaka-Kondoh, Shinae |
author_facet | Kadonosono, Tetsuya Yimchuen, Wanaporn Ota, Yumi See, Kyra Furuta, Tadaomi Shiozawa, Tadashi Kitazawa, Maika Goto, Yu Patil, Akash Kuchimaru, Takahiro Kizaka-Kondoh, Shinae |
author_sort | Kadonosono, Tetsuya |
collection | PubMed |
description | Monoclonal antibodies (mAbs) are attractive therapeutics for treating a wide range of human disorders, and bind to the antigen through their complementarity-determining regions (CDRs). Small stable proteins containing structurally retained CDRs are promising alternatives to mAbs. In this report, we present a method to create such proteins, named fluctuation-regulated affinity proteins (FLAPs). Thirteen graft acceptor (GA) sites that efficiently immobilise the grafted peptide structure were initially selected from six small protein scaffolds by computational identification. Five CDR peptides extracted by binding energy calculations from mAbs against breast cancer marker human epithelial growth factor receptor type 2 (HER2) were then grafted to the selected scaffolds. The combination of five CDR peptides and 13 GA sites in six scaffolds revealed that three of the 65 combinations showed specific binding to HER2 with dissociation constants (K(D)) of 270–350 nM in biolayer interferometry and 24–65 nM in ELISA. The FLAPs specifically detected HER2-overexpressing cancer cells. Thus, the present strategy is a promising and practical method for developing small antibody mimetics. |
format | Online Article Text |
id | pubmed-6972867 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-69728672020-01-27 Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use Kadonosono, Tetsuya Yimchuen, Wanaporn Ota, Yumi See, Kyra Furuta, Tadaomi Shiozawa, Tadashi Kitazawa, Maika Goto, Yu Patil, Akash Kuchimaru, Takahiro Kizaka-Kondoh, Shinae Sci Rep Article Monoclonal antibodies (mAbs) are attractive therapeutics for treating a wide range of human disorders, and bind to the antigen through their complementarity-determining regions (CDRs). Small stable proteins containing structurally retained CDRs are promising alternatives to mAbs. In this report, we present a method to create such proteins, named fluctuation-regulated affinity proteins (FLAPs). Thirteen graft acceptor (GA) sites that efficiently immobilise the grafted peptide structure were initially selected from six small protein scaffolds by computational identification. Five CDR peptides extracted by binding energy calculations from mAbs against breast cancer marker human epithelial growth factor receptor type 2 (HER2) were then grafted to the selected scaffolds. The combination of five CDR peptides and 13 GA sites in six scaffolds revealed that three of the 65 combinations showed specific binding to HER2 with dissociation constants (K(D)) of 270–350 nM in biolayer interferometry and 24–65 nM in ELISA. The FLAPs specifically detected HER2-overexpressing cancer cells. Thus, the present strategy is a promising and practical method for developing small antibody mimetics. Nature Publishing Group UK 2020-01-21 /pmc/articles/PMC6972867/ /pubmed/31964960 http://dx.doi.org/10.1038/s41598-020-57713-4 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Kadonosono, Tetsuya Yimchuen, Wanaporn Ota, Yumi See, Kyra Furuta, Tadaomi Shiozawa, Tadashi Kitazawa, Maika Goto, Yu Patil, Akash Kuchimaru, Takahiro Kizaka-Kondoh, Shinae Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use |
title | Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use |
title_full | Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use |
title_fullStr | Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use |
title_full_unstemmed | Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use |
title_short | Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use |
title_sort | design strategy to create antibody mimetics harbouring immobilised complementarity determining region peptides for practical use |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972867/ https://www.ncbi.nlm.nih.gov/pubmed/31964960 http://dx.doi.org/10.1038/s41598-020-57713-4 |
work_keys_str_mv | AT kadonosonotetsuya designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse AT yimchuenwanaporn designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse AT otayumi designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse AT seekyra designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse AT furutatadaomi designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse AT shiozawatadashi designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse AT kitazawamaika designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse AT gotoyu designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse AT patilakash designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse AT kuchimarutakahiro designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse AT kizakakondohshinae designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse |